MHLW Orders Label Revisions for Actemra, Tagrisso, Olumiant and More

September 25, 2019
The Ministry of Health, Labor and Welfare (MHLW) on September 24 ordered label revisions related to adverse reactions for a thong of medicines including Chugai Pharmaceutical’s rheumatoid arthritis (RA) drug Actemra (tocilizumab) and AstraZeneca’s lung cancer medicine Tagrisso (osimertinib). In...read more